ESMO Congress | Conference

Rucaparib Maintenance Elicits PFS Benefit in Newly Diagnosed Ovarian Cancer

September 11th 2022

First-line rucaparib maintenance therapy improved progression-free survival vs placebo in patients with newly diagnosed ovarian cancer, according to disease risk subgroup analyses from the phase 3 ATHENA–MONO study.

Lenvatinib/Pembrolizumab Combo Improves Survival, Responses in Advanced Endometrial Cancer

September 11th 2022

Lenvatinib plus pembrolizumab maintained clinically meaningful benefits in outcomes vs physician’s choice of therapy for patients with advanced endometrial cancer who received prior platinum-based chemotherapy.

Addition of Enzalutamide to Abiraterone/Prednisolone Deemed Unnecessary in Metastatic HSPC

September 11th 2022

Although the combination of androgen deprivation therapy, abiraterone acetate, and prednisolone showed a clinically meaningful 7-year improvement in overall survival, AAP plus enzalutamide is not recommended in patients with metastatic hormone-sensitive prostate cancer.

Adjuvant Nivolumab Plus Ipilimumab Fails to Improve DFS in Localized, High-Risk RCC

September 11th 2022

The combination of adjuvant nivolumab and ipilimumab did not elicit a significant disease-free survival benefit vs placebo in patients with localized, renal cell carcinoma at high risk for relapse after nephrectomy.

Pembrolizumab Plus Chemoradiation Shows Only Numerically Improved EFS, OS in Locally Advanced Head and Neck Cancer

September 11th 2022

Pembrolizumab plus chemoradiation failed to demonstrate a statistically significant improvement in event-free survival vs chemoradiation alone in patients with locally advanced head and neck squamous cell carcinoma.

Blood-based Assay Demonstrates Positive Prognostic Value for Solid and Liquid Tumor Detection

September 11th 2022

A pan-tumor blood-based assay demonstrated a specificity of 99.1% and positive predictive value of 38.0% and resulted in a diagnosis of cancer in 35 individuals.

Tremelimumab Plus Durvalumab/Chemo Maintains OS Benefit in Metastatic NSCLC

September 11th 2022

The frontline combination of tremelimumab plus durvalumab and chemotherapy generated a long-term overall survival benefit in patients with metastatic non–small cell lung cancer.

Xevinapant Plus Standard Chemoradiotherapy Demonstrates Sustained Benefit in Locally Advanced HNSCC

September 11th 2022

The addition of xevinapant to standard-of-care chemoradiotherapy elicited continued 5-year overall survival and 3-year duration of response benefits in patients with unresected head and neck locally advanced squamous cell carcinoma.

Frontline Tislelizumab Demonstrates Noninferior OS Vs Sorafenib in Unresectable HCC

September 11th 2022

Tislelizumab monotherapy provided a clinically meaningful overall survival benefit that was noninferior to sorafenib and showcased a favorable toxicity profile when used as a frontline treatment for patients with unresectable hepatocellular carcinoma.

Atezolizumab Fails to Improve DFS in RCC Following Resection

September 10th 2022

Treatment with atezolizumab did not improve clinical outcomes vs placebo following resection in patients with renal cell carcinoma at increased risk of recurrence.

Perioperative Nivolumab Fails to Improve RFS Vs Surgery Alone in RCC

September 10th 2022

Perioperative nivolumab did not improve recurrence-free survival compared with surgery alone in patients with renal cell carcinoma.

Pembrolizumab Plus Abiraterone/Prednisone Shows Sustained Efficacy in Chemotherapy-Naïve mCRPC

September 10th 2022

Pembrolizumab plus abiraterone acetate and prednisone demonstrated continued efficacy and tolerability in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.

Naporafenib Combinations Prove Effective in NRAS-Mutant Unresectable/Metastatic Melanoma

September 10th 2022

The investigational type II RAF inhibitor naporafenib exhibited favorable efficacy with a tolerable safety profile in combination with rineterkib, trametinib, or ribociclib in patients with previously treated, unresectable or metastatic melanoma.

Dr Allaf on Perioperative Nivolumab Vs Observation Following Nephrectomy in RCC

September 10th 2022

Mohamad Ezzeddine Allaf, MD, discusses the results of perioperative nivolumab vs observation in patients with renal cell carcinoma who undergo nephrectomy.

Trastuzumab Deruxtecan Maintains Clinical Benefit in Metastatic Gastric/GEJ Cancer

September 10th 2022

Trastuzumab deruxtecan continued to demonstrate a clinical benefit and tolerable safety profile for patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a trastuzumab-based regimen.

Amcenestrant Provides Numerically Similar PFS to Endocrine Therapy in Endocrine-Resistant ER+ Advanced Breast Cancer

September 10th 2022

Amcenestrant did not significantly improve progression-free survival over physician’s choice of endocrine monotherapy in patients with endocrine-resistant, estrogen receptor–positive, HER2-negative advanced breast cancer, but it did provide a benefit that was numerically comparable, according to data from the phase 2 AMEERA-3 trial.

Second-line Cemiplimab Produces Long-Term OS Benefit in Recurrent/Metastatic Cervical Cancer

September 10th 2022

Cemiplimab maintained an overall survival benefit vs chemotherapy as a second-line treatment for patients with recurrent or metastatic cervical cancer who received prior platinum-based chemotherapy.

Sacituzumab Govitecan-hziy Demonstrates Promising Efficacy in HER2-low/HER2-0 Metastatic Breast Cancer

September 10th 2022

Sacituzumab govitecan improved progression-free survival and overall response rate among patients with HER2-low or HER2 immunohistochemistry zero, hormone receptor–positive metastatic breast cancer.

ADP-A2M4CD8 Shows Promising Activity Across MAGE-A4+ Unresectable or Metastatic Tumor Types

September 10th 2022

An updated analysis of the phase 1 SURPASS trial showed that ADP-A2M4CD8, a next-generational autologous T-cell receptor designed to patients with solid tumors, may be an effective therapy in MAGE-A4-positive disease.

Lasofoxifene Improves Responses Vs Fulvestrant in ESR1-Mutated, ER+/HER2- Metastatic Breast Cancer

September 10th 2022

Single-agent lasofoxifene did not produce a statistically significant improvement in progression-free survival vs fulvestrant for patients with estrogen receptor–positive, HER2-negative metastatic breast cancer harboring ESR1 mutations.